Non developed Immunity can increase the risk of infection for premature infants. Vaccine DTaP-IPV-Hib-HepB (VaxelisTM), a hexavalent immunization tested in >6.800 infants, has a typical control-like appropriate vaccine protection and immunogenicity profiles. The study assesses the efficacy and immunogenicity of the vaccine for premature babies, DTaP-IPV-Hib-HepB.

The words “premature baby/careful care” and/or “low birthweight baby” were used to detect premature babies. Randomized, active-comparator-controlling, clinical trials and UK clinical trials have been combined through one phase III and four phaseIII.

In total, 160 children have been deemed to be premature. The rate of adverse effects (ADs) of DTaP-IPV-Hib-HepB for all AD days 1–15, requested AE-site days 1–5 post-vaccination and requested systemic AEs days 1-5 post-vaccination, was compared between the total and the premature populations. The protective immune response of high proportions of premature infants to antigens in the DTaP-IPV-Hib-HepB vaccine has been identified. The preterm response rates for both DTaP-IPV-Hib-HepB and control vaccinations in preterm babies is close to all infants.

The low occurrence of AE, an adequate safety profile and satisfactory immune responses in premature infants comparable to the sample population are emitted by DTaP-IPV-Hib-HepB vaccines.